DUBLIN, Jan. 8, 2019 The "Investigation Report on China's Pancreatic Kininogenase Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering
Pancreatic Kininogenase can be used to treat cardiovascular and cerebrovascular diseases such as primary hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal vascular disorder and peripheral vascular disease.
Recent studies have found that Pancreatic Kininogenase can also be used to prevent diabetic microangiopathy and early diabetic nephropathy by reducing the discharge of urinary albumin. In addition, Pancreatic Kininogenase can increase the activity and production of sperms, and thus has a certain curative effect on male infertility, according to domestic clinical data.
In 1999, Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase was first launched in China, followed by the counterparts of Chengdu Tongde Pharmaceutical Co., Ltd., Henan Livu Pharmacy Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., etc. At present, there are seven Pancreatic Kininogenase manufacturers in China. Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase (trade name: Yikai) takes up about 90% market share by sales value.
It is expected that as the incidence of cardiovascular and cerebrovascular diseases continues to increase, China's Pancreatic Kininogenase market will still have some growth potential in the next few years.
Key Topics Covered:
1 Relevant Concepts of Pancreatic Kininogenase
1.1 Indications for Pancreatic Kininogenase
1.2 Development of Pancreatic Kininogenase in China
1.3 Government Approval of Pancreatic Kininogenase in China
2 Sales of Pancreatic Kininogenase in China, 2013-2017
2.1 Sales Value of Pancreatic Kininogenase
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Pancreatic Kininogenase
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Pancreatic Kininogenase by Dosage Form in China, 2013-2017
2.3.1 Pancreatic Kininogenase Injections
2.3.2 Pancreatic Kininogenase Tablets
3 Analysis of Major Pancreatic Kininogenase Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Pancreatic Kininogenase Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shanghai Livzon Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Shanghai Livzon Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in China
3.3 Sichuan Shunsheng Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Sichuan Shunsheng Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in China
3.4 Changzhou Qianhong Bio-pharma Co., Ltd.
3.5 Chengdu Tongde Pharmaceutical Co., Ltd.
3.6 Henan Livu Pharmacy Co., Ltd.
4 Prices of Pancreatic Kininogenase in China, 2017-2018
4.1 Shanghai Livzon Pharmaceutical Co., Ltd. (Guangle)
4.2 Sichuan Shunsheng Pharmaceutical Co., Ltd. (Dashun)
4.3 Changzhou Qianhong Bio-pharma Co., Ltd. (Yikai)
4.4 Chengdu Tongde Pharmaceutical Co., Ltd. (Tongde)
4.5 Henan Livu Pharmaceutical Co., Ltd. (Duomeile)
5 Prospect of China's Pancreatic Kininogenase Market, 2018-2022
5.1 Factors Influencing Development Pancreatic Kininogenase Market
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/research/7wg7mr/china_pancreatic?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article